The Khavinson Lineage
The institutional research program that characterized the privileged subclass — the foundation on which the discipline rests.
The Khavinson lineage is the body of biochemical, in-vivo, and clinical research — extending across more than four decades and spanning institutional laboratories across Russia, Ukraine, Italy, South Korea, and the United Kingdom — that established short peptides of two to seven amino acids as a distinct pharmacological category capable of tissue-specific regulation of gene expression.
It is the empirical foundation of endogenic pharmacology. Without it, the discipline could not exist. With it, the discipline inherits a rigorously characterized therapeutic class and a structured mechanism of action.
Four decades, four eras.
- 1960s — 1980s
Origins in institutional biochemistry.
Initial isolation and characterization of short regulatory peptides from animal tissue extracts. Establishment of the foundational hypothesis: that endogenous peptide pools, decreasing with age and organ-specific dysregulation, could be replenished therapeutically through structurally-identical synthetic analogs.
- 1980s — 2000s
Clinical and biochemical validation.
Expansion to in-vivo mammalian study and structured clinical observation. Demonstration of tissue-specific regulatory action, longevity-relevant phenotypic effects, and the consistency of short-peptide bioregulation across multiple organ systems.
- 2000s — 2020s
Mechanistic and molecular characterization.
Resolution of the mechanism: nuclear translocation of short peptides, direct interaction with chromatin and gene-promoter regions, modulation of telomerase activity and gene expression in a tissue-specific manner. Cross-species replication across mouse, rat, primate, and bovine models.
- 2020s — Present
Modern formulation and therapeutic translation.
Engineering of dual-terminus modified analogs (Ac-X-NH2) extending half-life and enabling non-injectable delivery formats. Filing of provisional patent portfolios codifying the proprietary modifications. Translation to opticeutical and endoceutical clinical practice.
From institutional research to modern practice.
Endogenic pharmacology is the formalization of the discipline that this lineage made possible. The compounds it characterizes — the short peptide bioregulators, their modifications, their delivery formats, and their indications — are the compounds of the therapeutic class. The mechanism it resolved — tissue-specific gene regulation through nuclear translocation — is the mechanism of the discipline.
The continuity from institutional research to modern clinical practice is direct, traceable, and underwritten by published peer-reviewed evidence.